Alex Delbridge

Alex Delbridge PhD is a Principal on the Investment Team at Brandon Capital, effective August 2025. Delbridge has extensive experience in the biotechnology and pharmaceutical sectors, having served as a Board Observer for companies like BridgeBio Oncology Therapeutics, NRG Therapeutics, Scorpion Therapeutics, and Photys Therapeutics, with notable achievements including involvement in Scorpion Therapeutics' acquisition by Eli Lilly for up to $2.5 billion. Prior roles include Senior Investment Associate at Omega Funds and Consultant at Putnam Associates, where Delbridge provided commercial strategy guidance to leading pharmaceutical clients. Academic qualifications include a Ph.D. in Oncology and Cancer Biology from the University of Melbourne, along with credentials in business readiness and leadership from Harvard Business School Online and the University of Melbourne.